Related Experiment Video

Updated: May 7, 2026

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

Selective radiosensitization of p53-deficient cells by caffeine-mediated activation of p34cdc2 kinase

S L Yao1, A J Akhtar, K A McKenna

  • 1Johns Hopkins Oncology Center, Baltimore, Maryland 21287, USA.

Nature Medicine
|October 1, 1996
PubMed

Insights

Inactivating the p53 tumor suppressor gene causes cancer resistance to genotoxic drugs. Activating p34cdc2 kinase with caffeine selectively sensitizes p53-deficient cancer cells to irradiation-induced apoptosis.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Apoptosis, a programmed cell death, is crucial for anticancer therapy efficacy.
  • The p53 tumor suppressor gene is vital for initiating apoptosis following DNA damage.
  • Inactivation of p53 in cancer cells leads to resistance against genotoxic anticancer agents.

Purpose of the Study:

  • To investigate the role of p53 in cellular response to DNA damage and its impact on apoptosis.
  • To explore therapeutic strategies for overcoming resistance in p53-deficient cancers.

Main Methods:

  • Studied the cell-cycle arrest mechanisms (G1/S and G2/M) in response to DNA damage.
  • Investigated the role of p53 in mediating G1 arrest via p21WAF1/CIP1.
  • Examined the G2 arrest mechanism involving p34cdc2 kinase inactivation.
  • Utilized caffeine to abrogate G2 arrest by activating p34cdc2 kinase in p53-deficient cells.

Main Results:

  • p53-deficient cells fail to arrest at G1/S phase after DNA damage and accumulate at G2/M.
  • Abrogation of G2 arrest using caffeine selectively sensitized p53-deficient primary and tumor cells to irradiation-induced apoptosis.
  • Pharmacologic activation of p34cdc2 kinase demonstrated a potential to overcome resistance.

Conclusions:

  • p53 deficiency contributes to resistance to genotoxic anticancer agents by disrupting cell-cycle checkpoints.
  • Targeting the G2/M checkpoint and activating p34cdc2 kinase offers a promising therapeutic strategy to sensitize p53-deficient cancers to radiation therapy.

More Related Videos

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

Studying Cell Cycle-regulated Gene Expression by Two Complementary Cell Synchronization Protocols12:02

Studying Cell Cycle-regulated Gene Expression by Two Complementary Cell Synchronization Protocols

Published on: June 6, 2017

Related Concept Videos

Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
DNA Damage can Stall the Cell Cycle02:36

DNA Damage can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
DNA Damage Can Stall the Cell Cycle02:36

DNA Damage Can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...